美股A股
StockGist

Natera, Inc.

NTRANASDAQ · Healthcare · Medical - Diagnostics & Research
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.
$287.47-0.35%
报价 2026-11-17
市值
$41.68B
EV
$40.97B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -34.1%
$182.65$436.00

筛选结果

pipeline · 2026-11-17
Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool

爆发潜力

2026-11-17
未命中✗ 收入线✗ EPS 线
财年收入倍数EPSPE
FY+22027-121.3x-1.10 → -0.54—
FY+32028-121.5x-1.10 → 1.06(扭亏)272.0

毛利率 65% · TTM 收入 $2909M · 基数 EPS -1.10(调整后)

电话会信号

辅助标签
Q3 20262026-11-05
扩产需求加速上调指引盈利拐点
指引 上调
信心 5
分析师 4

“We are setting the goal to double revenues in the next 3 years, reaching $6 billion in revenue in 2029.”

原文引用(4)
  • 扩产:we have accelerated a lot of investments in our pharma specific offerings, commercial team, and operations that drive both CapEx and operating expenses higher
  • 需求加速:Over the last 9 months, we have seen a real surge in biopharma demand for our MRD technology, in clinical trials
  • 上调指引:we are raising our full-year 2026 revenue guidance to a range of $3.05 billion to $3.35 billion up from the $2.85 billion to $2.91 billion
  • 盈利拐点:it will be possible for us to continue to deliver another quarter of positive free cash flow and improving EBITDA in Q4

蓝色标签在暴涨研究中略有区分度;悬停查看口径。

研究结论

L2 2026-11-12 · L3 2026-11-12全文 ↓
Bull
$162.00
-49.35% · PE
Base
$53.50
-83.27% · PE
Bear
$122.57
-61.68% · EV/Sales
Bull
Base
Bear
现价 $287.47

### 5.1 概率加权结果

基本面判断
  • ›最强证据

    检测量(尤其肿瘤 MRD +60.9%)与 ASP 双升驱动收入 +34%,亏损连续收窄,指引连续大幅上修,方向性基本面向上 (Q3 2026 call; 8-K 2026-11-05)。

  • ›最大反证/不确定性

    利润改善靠收入摊薄而非费用节制,CFO 依赖 SBC 与应收变动,FCF 被 capex 吞噬;true-up 与 ASP 路径的可持续性缺少跨期硬证据;诉讼结果未定。

  • ›研究置信度

    中等偏低——收入增长证据较扎实,但盈利质量、现金转化与 ASP 长期路径的关键输入不足,部分项目"无法检验"。

  • ›是否进入 Layer 3 估值?有条件

    收入与检测量可建模,ASP 路径与费用纪律有管理层指引可锚定,值得检验"2027 利润率拐点"的预期差;但需先补齐应收账龄、SBC 口径与 consensus EPS 定义,否则利润率与 FCF 模型输入不足。

接下来盯什么(5 项)
  1. 剔除 true-up 后的季度营收增速与环比检测增量:→ 当前基准:Q3 剔除 true-up 同比 >40%、MRD 环比 +3.3 万例 → 验证条件:下季环比增量是否维持 2.5 万例以上、true-up 占比是否继续下降 → 调整假设 A 与收入路径。
  2. Signatera ASP 与 MolDX 覆盖进展:→ 当前基准:约 $1.29k,9–10 项提交在途 → 验证条件:未来 12 个月是否有新增适应症覆盖落地、ASP 是否续升 → 调整假设 A。
  3. 经营费用增速 vs 收入增速:→ 当前基准:Q3 R&D +39.8%、SG&A +8.1% → 验证条件:2027 年 OpEx 是否落在 +10%–12% 区间 → 调整假设 B 与利润率拐点时点。
  4. 应收账款与经营现金流:→ 当前基准:前九月应收 +$174.8M、FCF $14.7M → 验证条件:应收增速是否低于收入增速、Q4 FCF 是否为正 → 调整假设 C。
  5. 诉讼与或有对价:→ 当前基准:Guardant/Ravgen 上诉中、或有对价上限 $175M → 验证条件:上诉结果或和解、里程碑触发 → 调整净负债与稀释假设。

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
NTRANatera, Inc.$41.68B-0.4%–64.7%––797.3x
TEVATeva Pharmaceutical Industries Limited$49.73B+0.1%-0.6%55.5%93.0x30.3x39.5x
WATWaters Corporation$44.21B-0.8%+105.3%58.9%28.0x18.3x151.6x高增长
IQVIQVIA Holdings Inc.$42.45B-2.7%+8.0%32.9%33.1x16.6x16.9x
MTDMettler-Toledo International Inc.$34.07B-0.8%+6.7%57.5%29.1x22.2x39.1x
ILMNIllumina, Inc.$30.63B+2.3%+7.6%66.4%49.5x30.8x43.1x
DXCMDexCom, Inc.$30.6B+0.5%+12.4%63.4%34.4x21.8x23.9xGARP
PHGKoninklijke Philips N.V.$28.95B-0.8%–45.2%24.5x10.1x–
DGXQuest Diagnostics Incorporated$28.2B-2.2%+10.0%33.7%24.3x15.6x21.0xGARP
同行中位数––+8.0%56.5%31.1x20.0x39.1x

研究全文

财务报表

Metric
2026-09-30
Q3 2026
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
Revenue$794M$752.8M$696.6M$665.5M$592.2M$546.6M$501.8M$476.1M
Gross Margin64.7%64.5%64.8%67.1%64.9%63.5%63.2%62.9%
Operating Margin-8.6%-10.1%-13.4%-3.4%-16.5%-20.2%-15.8%-13.6%
Net Income$-59.9M$-67M$-85.1M$47.3M$-87.5M$-100.9M$-66.9M$-53.8M
Diluted EPS-0.42-0.47-0.60.35-0.64-0.74-0.5-0.41
Operating Cash Flow$43.9M$54.8M$40.2M$73.9M$59.4M$37.6M$44.5M$52.9M

研究材料